New version of Enzon cancer drug secures orphan status in EU

09/30/2008 | Boston Globe (tiered subscription model), The

European regulators granted orphan-drug status for Enzon Pharmaceuticals' Oncaspar-IV, a new version of its cancer drug for acute lymphoblastic leukemia. The designation prevents other drugmakers from selling copies of Oncaspar-IV for a decade should the product receive market clearance. Oncaspar-IV destroys cancer cells by depriving them of a key amino acid.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA